Globus Medical (NYSE:GMED) Shares Down 8.5% – Here’s Why

Globus Medical, Inc. (NYSE:GMED)’s stock price dropped 8.5% on Friday . The stock traded as low as $78.12 and last traded at $77.84. Approximately 1,099,487 shares changed hands during trading, a decline of 10% from the average daily volume of 1,217,394 shares. The stock had previously closed at $85.07.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q1 results beat Street expectations — GAAP EPS $1.12 vs. ~$0.92 consensus and revenue $759.85M (up 27% YoY), signalling solid top‑line growth and margin expansion. Read More.
• Positive Sentiment: Company raised FY‑2026 EPS guidance to $4.70–$4.80 vs. consensus ~4.47 — a clear upward revision that implies stronger expected profitability for the year. Read More.
• Positive Sentiment: Street bullishness increased — Needham raised its price target to $117 and reiterated a Buy, citing upside vs. current levels; analyst support can underpin medium‑term interest. Read More.
• Positive Sentiment: Broker / market research attention — Zacks and other outlets highlighted the beat and upgraded estimates / coverage, which can attract quant and fundamental buyers. Read More.
• Neutral Sentiment: Full conference call and transcripts are available for details on procedure mix, backlog and cadence — useful for assessing sustainability but not new headline surprises. Read More.
• Negative Sentiment: Market reaction today is negative: shares are down with below‑average volume and trading under the 50‑day SMA — suggesting short‑term profit‑taking or technical selling despite the fundamentally positive print. (No article)

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Citigroup reissued a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Canaccord Genuity Group increased their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Finally, Barclays raised their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $104.55.

Globus Medical Stock Performance

The company has a 50-day moving average of $89.86 and a 200 day moving average of $86.65. The firm has a market cap of $10.64 billion, a P/E ratio of 19.96, a P/E/G ratio of 2.09 and a beta of 1.00.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the prior year, the business posted $0.68 earnings per share. The business’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts anticipate that Globus Medical, Inc. will post 4.46 EPS for the current fiscal year.

Insider Activity

In related news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is owned by company insiders.

Institutional Trading of Globus Medical

Several hedge funds have recently modified their holdings of GMED. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC increased its holdings in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. First Horizon Corp bought a new position in Globus Medical in the 3rd quarter valued at $31,000. Finally, Parallel Advisors LLC boosted its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.